• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

放射性药物良好规范:医院与行业之间的监管

Radiopharmaceutical good practices: Regulation between hospital and industry.

作者信息

Faivre-Chauvet Alain, Bourdeau Cécile, Bourgeois Mickaël

机构信息

Nantes-Angers Cancer Research Center CRCI2NA, University of Nantes, INSERM UMR1307, CNRS-ERL6075, Nantes, France.

Nuclear Medicine Department, University Hospital, Nantes, France.

出版信息

Front Nucl Med. 2022 Sep 7;2:990330. doi: 10.3389/fnume.2022.990330. eCollection 2022.

DOI:10.3389/fnume.2022.990330
PMID:39354961
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11440975/
Abstract

Radiopharmaceutical practices are divided into large-scale industrial manufacturing and small-scale "in-house" hospital radiopharmacy unit. The recent evolution of nuclear medicine involves deep consequences in this ever-present regulatory state, and hospital radiopharmacy units cannot be considered as contract manufacturing organizations (CMO). This review provides an updated status report of the official (and non-official) guidelines supporting the regulations required to meet hospital and industry common radiopharmaceutical manufacturing standards to facilitate the current and future innovative radiopharmaceutical development.

摘要

放射性药物实践分为大规模工业制造和小规模的医院内部放射性药房部门。核医学的最新发展在这种一直存在的监管状态下产生了深远影响,医院放射性药房部门不能被视为合同制造组织(CMO)。本综述提供了官方(和非官方)指南的最新状态报告,这些指南支持满足医院和行业通用放射性药物制造标准所需的法规,以促进当前和未来创新放射性药物的开发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bedc/11440975/1c06e9f418b4/fnume-02-990330-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bedc/11440975/1c06e9f418b4/fnume-02-990330-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bedc/11440975/1c06e9f418b4/fnume-02-990330-g001.jpg

相似文献

1
Radiopharmaceutical good practices: Regulation between hospital and industry.放射性药物良好规范:医院与行业之间的监管
Front Nucl Med. 2022 Sep 7;2:990330. doi: 10.3389/fnume.2022.990330. eCollection 2022.
2
ARRONAX Cyclotron: Setting up of In-House Hospital Radiopharmacy.阿罗纳克斯回旋加速器:内部医院放射药房的设置。
Biomed Res Int. 2020 Mar 10;2020:1572841. doi: 10.1155/2020/1572841. eCollection 2020.
3
Strengthening radiopharmacy practice in IAEA Member States.加强国际原子能机构成员国的放射药物实践。
Semin Nucl Med. 2013 May;43(3):188-94. doi: 10.1053/j.semnuclmed.2012.11.009.
4
Towards a harmonized radiopharmaceutical regulatory framework in Europe?欧洲是否能建立一个统一的放射性药物监管框架?
Q J Nucl Med Mol Imaging. 2009 Aug;53(4):394-401.
5
Design and Construction of a Radiochemistry Laboratory and cGMP-Compliant Radiopharmacy Facility.放射化学实验室及符合cGMP标准的放射性药物制剂设施的设计与建设。
Pharmaceuticals (Basel). 2024 May 25;17(6):680. doi: 10.3390/ph17060680.
6
Operation of a radiopharmacy for a clinical trial.临床试验用放射性药物药房的运作。
Semin Nucl Med. 2010 Sep;40(5):347-56. doi: 10.1053/j.semnuclmed.2010.06.002.
7
Experience with radiopharmacy information system.放射性药物信息系统的经验
EJNMMI Radiopharm Chem. 2022 Jul 19;7(1):17. doi: 10.1186/s41181-022-00169-w.
8
Radiopharmaceutical small-scale preparation in Europe: will we be able to harmonize the situation?欧洲放射性药物的小规模制备:我们能够使情况协调一致吗?
EJNMMI Radiopharm Chem. 2024 Sep 5;9(1):64. doi: 10.1186/s41181-024-00281-z.
9
Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective.关于使用自动化模块小规模制备放射性药物的现行良好放射性药物制备规范指南:欧洲视角。
J Labelled Comp Radiopharm. 2014 Aug;57(10):615-20. doi: 10.1002/jlcr.3227. Epub 2014 Sep 5.
10
The effect of COVID-19 on nuclear medicine and radiopharmacy activities: A global survey.COVID-19 对核医学和放射性药物活动的影响:全球调查。
Sci Rep. 2023 Jun 28;13(1):10489. doi: 10.1038/s41598-023-36925-4.

引用本文的文献

1
Production, Validation, and Exposure Dose Measurement of [N]Ammonia Under Academic Good Manufacturing Practice Environments.在学术性良好生产规范环境下进行的[氮]氨的生产、验证及暴露剂量测量。
Pharmaceutics. 2025 May 19;17(5):667. doi: 10.3390/pharmaceutics17050667.
2
Fully Automated Production of ((()-1-Carboxy-5-(6-([F]fluoro)-2-methoxynicotinamido)pentyl)carbamoyl)-l-glutamic Acid ([F]JK-PSMA-7).((()-1-羧基-5-(6-([F]氟)-2-甲氧基烟酰胺基)戊基)氨基甲酰基)-L-谷氨酸([F]JK-PSMA-7)的全自动生产
Pharmaceuticals (Basel). 2025 Jan 17;18(1):119. doi: 10.3390/ph18010119.
3
Aspects and prospects of preclinical theranostic radiopharmaceutical development.

本文引用的文献

1
EANM guideline on quality risk management for radiopharmaceuticals.EANM 放射性药物质量风险管理指南。
Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3353-3364. doi: 10.1007/s00259-022-05738-4. Epub 2022 Apr 7.
2
EANM position on the in-house preparation of radiopharmaceuticals.欧洲核医学协会关于放射性药物内部制备的立场。
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1095-1098. doi: 10.1007/s00259-022-05694-z.
3
Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals.
临床前治疗放射性药物开发的方面和前景。
Theranostics. 2024 Oct 7;14(17):6446-6470. doi: 10.7150/thno.100339. eCollection 2024.
放射性药物小规模制备现行良好放射性药物生产规范(cGRPP)指南。
EJNMMI Radiopharm Chem. 2021 Feb 12;6(1):8. doi: 10.1186/s41181-021-00123-2.
4
EANM guideline on the validation of analytical methods for radiopharmaceuticals.欧洲核医学协会放射性药物分析方法验证指南。
EJNMMI Radiopharm Chem. 2020 Feb 12;5(1):7. doi: 10.1186/s41181-019-0086-z.
5
US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations.美国和欧盟针对临床试验授权及上市许可的放射性药物诊断和治疗非临床研究要求。
EJNMMI Radiopharm Chem. 2019 May 22;4(1):10. doi: 10.1186/s41181-019-0059-2.
6
The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented?关于放射性药物临床试验的新法规:何时以及如何实施?
EJNMMI Radiopharm Chem. 2019 Jan 11;4(1):2. doi: 10.1186/s41181-019-0055-6.
7
National Cancer Institute Programmatic Collaboration for Investigational Radiopharmaceuticals.美国国立癌症研究所放射性药物研究项目协作组
Am Soc Clin Oncol Educ Book. 2018 May 23;38:488-494. doi: 10.1200/EDBK_200199.
8
Perspective on How the FDA Should Review Diagnostic Radiopharmaceuticals.关于美国食品药品监督管理局应如何审评诊断性放射性药物的观点
J Nucl Med. 2018 Jun;59(6):865-867. doi: 10.2967/jnumed.117.204446. Epub 2018 Mar 30.
9
Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals.放射性药物特殊情况下毒理学研究要求的立场文件。
EJNMMI Radiopharm Chem. 2017;1(1):1. doi: 10.1186/s41181-016-0004-6. Epub 2016 Mar 21.
10
Guidance on validation and qualification of processes and operations involving radiopharmaceuticals.放射性药物相关工艺和操作的验证与确认指南。
EJNMMI Radiopharm Chem. 2017;2(1):8. doi: 10.1186/s41181-017-0025-9. Epub 2017 Jun 29.